Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Marianne E. Pavel, Simron Singh*, Jonathan R. Strosberg, Lida Bubuteishvili-Pacaud, Evgeny Degtyarev, Maureen P. Neary, Carlo Carnaghi, Jiri Tomasek, Edward Wolin, Markus Raderer, Harald Lahner, Juan W. Valle, Rodney Pommier, Eric Van Cutsem, Margot E.T. Tesselaar, Gianfranco Delle Fave, Roberto Buzzoni, Matthias Hunger, Jennifer Eriksson, David CellaJean François Ricci, Nicola Fazio, Matthew H. Kulke, James C. Yao

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Fingerprint

Dive into the research topics of 'Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science